Intraperitoneal Administration of alpha-Tricalcium Phosphate (alpha-TCP) Particles as a Drug Carrier in Rats Bearing Abdominal Carcinomatosis for the Purpose of the Clinical Application

腹腔注射α-磷酸三钙（α-TCP）颗粒作为药物载体在患有腹部癌的大鼠中的临床应用

• 批准号: 07671318
• 负责人: MANABE Tadao
• 金额: $ 1.54万
• 依托单位: Nagoya City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07671318/
• 关键词: carboplatin; alpha-TCP-particles; AH130 carcinoma; controlled release

alpha-Tricalcium phosphate (alpha-TCP) is biomaterial and its chemical properties is as similar as hydroxyapatite. It is known that alpha-TCP has excellent compatibility with human tissues and is biodegradable. We usesd alpha-TCP particles as a drug carrier, mixing with 4mg carboplatin (CBDCA) to 200mg alpha-TCP particles, and made the slow relesae drugs : alpha-TCP-CBDCA.The pharmacokinetics of alpha-TCP-CBDCA were examined using Donryu rat models with AH130 abdominal carcinomatosis. alpha-TCP particles were administered into the peritoneal cavity (i.p.) and were taken up especially in the greater omentum. The Pt levels in ascites and the greater omentum were higher in the alpha-TCP-CBDCA i.p. from 1 to 168 hours than in the CBDCA i.p. and i.v. groups.alpha-TCP-CBDCA i.p. was effective in prolonging the survival of rats. These results suggest that the efficacy of CBDCA may be enhanced by utilizing alpha-TCP particles as a drug carrier.

α-磷酸三钙（alpha-TCP）是一种生物材料，其化学性质与羟基磷灰石相似。已知α-TCP与人体组织具有优异的相容性并且是可生物降解的。以α-TCP微粒为药物载体，与4 mg卡铂（carboplatin，CBDCA）混合制成200 mg α-TCP微粒，制成缓释药物α-TCP-CBDCA。将α-TCP颗粒施用到腹膜腔中（i. p.）尤其是大网膜腹腔注射alpha-TCP-CBDCA后1 ~ 168 h腹水和大网膜中铂含量高于CBDCA组和静脉注射组，能有效延长大鼠的生存期。这些结果表明，CBDCA的功效可以通过利用α-TCP颗粒作为药物载体来增强。

项目成果

水野勇,青木秀希他: "薬剤carrierとしての水酸アパタイト細粒を用いた除放化レンチナンによる癌性腹膜炎の治療に関する実験的検討。" 人工臓器. 22. 339-343 (1993)

Isamu Mizuno、Hideki Aoki 等人：“使用羟基磷灰石细颗粒作为药物载体缓释香菇多糖治疗癌性腹膜炎的实验研究”22. 339-343 (1993)。

植田拓也・水野勇 四ツ柳智久・真辺忠夫他: "Drug Carrierとしてαーリン酸三カルシウム細粒を用いた除放化カルボプラチンによる癌性腹膜炎治療の基礎的検討" 人工臓器. (in press). (1997)

Takuy​​a Ueda、Isamu Mizuno、Tomohisa Yotsuyanagi、Tadao Manabe 等：“使用 α-磷酸三钙细颗粒作为药物载体缓释卡铂治疗癌性腹膜炎的基础研究”（出版中）。 ) )

Mizuno Isamu et.al.: "Intraperitoneal Administration of Carboplatin-loaded Hydroxyapatite(HAp)and α-Tricalcium Phosphate(α-TCP)Particles in Rats Bearing Abdominal Carcinomatosis." American Association for Cancer Research. (in press). (1996)

Mizuno Isamu 等人：“腹膜内施用卡铂负载的羟基磷灰石 (HAp) 和 α-磷酸三钙 (α-TCP) 颗粒对患有腹部癌的大鼠”(1996 年出版)。

Isamu Mizuno^<**1>, Tamotsu Yasui^<**1>, Hiromitsu Takeyama^<**1>, Masakazu Ishikawa^<**1>, Junji Terada^<**1>, Noriaki Mohri^<**1>, Takuya Ueda^<**1>, Naoki Sumita^<**1>, Kenji Kobayashi^<**1>, Yoshimi Akamo^<**1>, Tadao Manabe^<**1>, Toshihisa Yotsuyana

水野勇^<**1>、安井保^<**1>、竹山弘光^<**1>、石川正和^<**1>、寺田润二^<**1>、毛利则明^<*

植田拓也 水野勇: "ラット癌性腹膜炎におけるカルボプラチン含有αーリン酸三カルシウム(α-TCP)の腹腔内投与における基礎的検討-1-" Drug Delivery System. (in press). (1997)

Takuy​​a Ueda、Isamu Mizuno：“含卡铂的α-磷酸三钙（α-TCP）在大鼠癌性腹膜炎中腹膜内给药的基础研究-1-”（正在出版）。